Neuroendocrine Tumors

NETs Overview - The Hormone Rebels

• Definition: Heterogeneous neoplasms from neuroendocrine cells (historically APUDomas) within the Diffuse Neuroendocrine System (DNES).
• Key Feature: Can synthesize and secrete various hormones/amines, causing diverse syndromes (functional) or be silent (non-functional).
• Common Sites:
  • Gastroenteropancreatic (GEP) tract (most common): Small intestine (ileum), rectum, pancreas, appendix.
  • Lungs (bronchial carcinoids).
• WHO Classification (GEP-NETs): Graded by proliferation.
  • NET G1: Mitoses <2/10 HPF & Ki-67 index ≤2%
  • NET G2: Mitoses 2-20/10 HPF & Ki-67 index 3-20%
  • NEC G3 (Carcinoma): Mitoses >20/10 HPF & Ki-67 index >20%

⭐ Small intestine (especially ileum) is the most common site for GEP-NETs., where they are often multifocal and associated with carcinoid syndrome if liver metastases are present

Symptoms & Diagnosis - Spotting the Signals

• Symptoms:
  • Non-functioning: Often silent; vague pain, mass effect.
  • Functioning: Hormone excess syndromes.
    • Carcinoid: Flushing, diarrhea, bronchospasm. 📌 (Serotonin-mediated)
    • Insulinoma: Hypoglycemia (Whipple's triad).
    • Gastrinoma (ZES): Peptic ulcers, diarrhea.
• Diagnosis:
  • Biochemical Markers:
    • General: ↑Chromogranin A (CgA) - most sensitive. Neuron-Specific Enolase (NSE).
    • Specific: Urine 5-HIAA (carcinoid); serum insulin, gastrin, glucagon.
  • Imaging:
    • Anatomical: CT, MRI, Endoscopic Ultrasound (EUS).
    • Functional (Receptor-based): ⁶⁸Ga-DOTATATE PET/CT (gold standard for GEP-NETs), Octreoscan (¹¹¹In-pentetreotide SRS).

⭐ Carcinoid syndrome (flushing, diarrhea) typically manifests only after liver metastasis, as hepatic first-pass metabolism inactivates hormones from primary GI NETs.

Key Syndromes - The Hormone Havoc

⭐ Carcinoid syndrome typically manifests only after liver metastases, as hormones from GI carcinoids are inactivated by the first-pass effect in the liver.

Treatment Strategies - Taming the Tumors

• Localized Disease: Surgical resection offers curative potential. Adjuvant therapy based on risk.
• Metastatic/Unresectable Well-Differentiated (WD-NETs):
  • Somatostatin Analogs (SSAs): Octreotide, Lanreotide for carcinoid syndrome control & antiproliferative effects (PROMID, CLARINET studies).
  • Peptide Receptor Radionuclide Therapy (PRRT): $^{177}$Lu-DOTATATE for SSTR+ tumors after SSA progression (NETTER-1 trial).
  • Targeted Therapy: Everolimus (mTORi), Sunitinib (TKI) for progressive pancreatic NETs (pNETs)/GI-NETs.
• Poorly Differentiated Neuroendocrine Carcinomas (PD-NECs) / High-Grade: Systemic chemotherapy (e.g., Cisplatin + Etoposide) is standard.

⭐ Octreotide/Lanreotide (SSAs) are first-line for symptomatic and antiproliferative therapy in unresectable/metastatic low-intermediate grade GEP-NETs.

High‑Yield Points - ⚡ Biggest Takeaways

• Carcinoid syndrome (flushing, diarrhea) often indicates liver metastases from midgut NETs.
• Chromogranin A (CgA) is the most sensitive general marker for NETs.
• Octreotide scan (SRS) is crucial for localization and staging.
• MEN 1 association: Pancreatic NETs (gastrinoma, insulinoma), parathyroid, pituitary.
• Insulinomas present with Whipple's triad; surgical enucleation is often curative.
• Gastrinomas (ZES) cause severe peptic ulcers; locate in Passaro's triangle.
• Surgical resection is the mainstay for curative intent in localized disease_